In this study, the influence of NMN on arterial stiffness and blood pressure was investigated.
Research Results:
-
Supplementation of NAD+-boosting agents reduced the stiffness of blood vessels, suggesting that NMN supplementation may improve vascular health in middle-aged adults.
-
NMN intervention resulted in a significant reduction in diastolic blood pressure in participants with above-average blood glucose levels.
Study Design:
-
Participants: 36 healthy middle-aged adults
-
Type: Randomized, double-blind, placebo-controlled, parallel-group clinical trial
-
Duration: 12 weeks
-
Dosage: 125 mg NMN or placebo twice daily
About the Study:
Numerous animal studies have demonstrated that orally administering nicotinamide adenine dinucleotide (NAD+) with the precursor nicotinamide mononucleotide (NMN) prevents the loss of NAD+ levels in organs and tissues, aiding in reducing diseases associated with aging. However, there are few clinical trials on NMN supplementation in humans. Therefore, the aim of this study was to examine the effects of a 12-week NMN supplementation on biochemical and metabolic health parameters. The study was conducted as a randomized, double-blind, placebo-controlled, parallel-group clinical trial, where a total of 36 healthy middle-aged adults received one capsule of 125 mg NMN or placebo twice daily. The NMN supplementation group showed significantly higher levels of nicotinamide in serum compared to the placebo group, while the values of pulse wave velocity, indicating arterial stiffness, tended to decrease in the NMN group, but no significant difference was observed between the two groups. Long-term NMN supplementation at a dose of 250 mg per day was well tolerated and did not lead to adverse effects. NMN safely and effectively increased NAD+ metabolism in healthy middle-aged adults, demonstrating potential in alleviating arterial stiffness.
